Pfizer enters the back half of 2025 with a clearer narrative: refocus the portfolio around high-value oncology, vaccines, and metabolic disease, convert a deep late-stage pipeline into approvals, and use disciplined deals to bridge one of the industry’s toughest patent cliffs. New approvals and label expansions are arriving, cost actions are largely complete, and the Seagen acquisition is reshaping Pfizer’s oncology mix. The question is whether these moves can outpace LOE (loss of exclusivity) headwinds between 2026 and 2028 and restore durable growth through the decade.
🔔 Don’t miss out!
Add winvestacrisps@substack.com to your email list so our updates never land in spam
